Evolent Health vs Gartner
EVH and IT side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVH and IT compare
Gartner is the larger company, worth 22 times as much as Evolent Health ($12.2B against $564M).
Evolent Health grew revenue faster over the last twelve months (14.1% versus 0.68% for Gartner).
Gartner keeps more of each dollar of sales as profit, with a net margin of 12.0% compared with −21.7% at Evolent Health.
Gartner scores higher on the StockData Score (14 against 7 for Evolent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVH | IT |
|---|---|---|
| Size and price | ||
| Market cap | $564M | $12.2B |
| Share price | $4.99 | $193.00 |
| Change, 1 year | 0.81% | −15.6% |
| Change, 5 years | −82.7% | −42.3% |
| Beta (5Y) | 0.82 | 0.97 |
| Employees | 4,200 | 20K |
| StockData Score | ||
| Total score | 7 | 14 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 0 | 5 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.3× |
| P/S | 0.2× (better) | 1.9× |
| P/B | 1.5× | – |
| EV/EBITDA | – | 10.5× |
| Fair value | $7.16 | $302.67 |
| Margin of safety | 30.3% | 36.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.1% (better) | 0.68% |
| Revenue growth, 5Y average | 15.2% (better) | 9.6% |
| Net income growth (TTM) | – | −38.7% |
| EPS growth (TTM) | – | −31.4% |
| EPS growth, 5Y average | – | 26.7% |
| Profitability | ||
| Gross margin | 15.0% | 70.1% (better) |
| Operating margin | −18.5% | 17.3% (better) |
| Net margin | −21.7% | 12.0% (better) |
| Return on equity | −83.6% | 114% (better) |
| Return on invested capital | −23.0% | 53.8% (better) |
| Financial health | ||
| Debt / equity | 2.60 | – |
| Net debt / EBITDA | – | 1.14 |
| Interest coverage | −6.2× | 7.8× (better) |
| Current ratio | 1.26 (better) | 0.88 |
| Altman Z-score | −0.24 | 3.74 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | 21.6% |
| Shareholder yield | 0.00% | 21.6% (better) |
| Ownership | ||
| Held by institutions | 99.3% | 119% |
| Held by insiders | 3.3% | 3.6% |
| Insider net buying, 12 months | −$329K | $8.4M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.7% | 10.3% |
Go deeper
- EVH stock overview
- EVH income statement
- EVH valuation and score
- IT stock overview
- IT income statement
- IT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.